BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28673220)

  • 1. Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit.
    Shiralkar SP; Kerr P; Scott J; Sivalingam P
    Anaesth Intensive Care; 2017 Jul; 45(4):490-498. PubMed ID: 28673220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
    Chua TC; Yan TD; Smigielski ME; Zhu KJ; Ng KM; Zhao J; Morris DL
    Ann Surg Oncol; 2009 Jul; 16(7):1903-11. PubMed ID: 19387742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Iavazzo C; Spiliotis J
    Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
    [No Abstract]   [Full Text] [Related]  

  • 7. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
    Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
    Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin.
    Järvinen P; Ristimäki A; Kantonen J; Aronen M; Huuhtanen R; Järvinen H; Lepistö A
    Int J Colorectal Dis; 2014 Aug; 29(8):999-1007. PubMed ID: 24965858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should total gastrectomy and total colectomy be considered for selected patients with severe tumor burden of pseudomyxoma peritonei in cytoreductive surgery?
    Liu Y; Mizumoto A; Ishibashi H; Takeshita K; Hirano M; Ichinose M; Takegawa S; Yonemura Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1018-23. PubMed ID: 27241925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperthermic intraperitoneal chemotherapy combined with cytoreductive procedure in patients with peritoneal pseudomyxoma].
    Gafton GI; Senchik KY; Kireeva GS; Petrov VG; Semiglazov VV; Guseynov KD; Bespalov VG; Belyaeva OA; Belyaev AM
    Khirurgiia (Mosk); 2016; (5):26-30. PubMed ID: 27271716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
    Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
    Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yoshizaki Y; Gohda Y; Inagaki F; Kataoka A; Takemura N; Miyazaki H; Igari T; Kiyomatsu T; Yano H; Kokudo N
    Clin J Gastroenterol; 2024 Feb; 17(1):188-197. PubMed ID: 37980306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
    Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.